** Shares of Moderna MRNA.O fall 3.28% to $32.48 premarket
** U.S. health officials are reevaluating a $590 million contract that was awarded to co for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources
** The review is part of a government push to examine spending on messenger RNA-based vaccines, the technology that powered Moderna's COVID vaccine, the report added
** The U.S. government awarded MRNA $590 million in January to advance the development of its bird flu vaccine
** Shares have fallen nearly 65% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))